Eva Csizmadia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eva Csizmadia has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Elena Levantini
Institute of Biomedical Technologies, National Research Council (CNR) Pisa Italy
58 shared publications - John Gerard Clohessy
Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
58 shared publications - Art Branstrom
PTC Therapeutics, Inc
49 shared publications - Azhar Ali
Cancer Science Institute of Singapore, National University of Singapore, Singapore
49 shared publications - Barbara Storti
NEST, Scuola Normale Superiore and Istituto Nanoscienze-CNR, Piazza San Silvestro 12, 56127 Pisa, Italy
49 shared publications - Daniel Geoffrey Tenen
Harvard Stem Cell Institute, Harvard Medical School, Boston, USA
49 shared publications
Latest Publications
- Open Access
- 10 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment
Supplementary Table 2. Size of each identified transcriptional cluster as percentage of all profiled cells.
- 10 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment
Supplementary Table 2. Size of each identified transcriptional cluster as percentage of all profiled cells.
- Open Access
- 10 April 2025
- Published by American Association for Cancer Research (AACR)
FIGURE 2 from Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment
ScRNA-seq of healthy and tumor-bearing lungs highlights presence of pulmonary milieu clusters. A, t-SNE plot of the 41 clusters identified in healthy lungs (n = 3, left), and Vehicle- (n = 10, middle), or Unesbulin-treated tumors (n = 3, right), at 30 days. Each point represents one cell. Each color represents a defined transcriptional cluster as shown in the corresponding legends. B, t-SNE plot in which transcriptional clusters have been annotated as epithelial, immune, endothelial, or fibroblast subpopulations. C, Cluster distribution superimposed to clusters annotation within epithelial, immune, endothelial cells, and fibroblasts in healthy lungs (left), and Vehicle- (middle), or Unesbulin-treated tumors (right).
- 10 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 2 from Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment
ScRNA-seq of healthy and tumor-bearing lungs highlights presence of pulmonary milieu clusters. A, t-SNE plot of the 41 clusters identified in healthy lungs (n = 3, left), and Vehicle- (n = 10, middle), or Unesbulin-treated tumors (n = 3, right), at 30 days. Each point represents one cell. Each color represents a defined transcriptional cluster as shown in the corresponding legends. B, t-SNE plot in which transcriptional clusters have been annotated as epithelial, immune, endothelial, or fibroblast subpopulations. C, Cluster distribution superimposed to clusters annotation within epithelial, immune, endothelial cells, and fibroblasts in healthy lungs (left), and Vehicle- (middle), or Unesbulin-treated tumors (right).
- Open Access
- 10 April 2025
- Published by American Association for Cancer Research (AACR)
FIGURE 1 from Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment
BMI-1 inhibition affects cell cycle progression and tumor growth. A, Western blot analyses of the human H1975 cell line treated for 24, 48, and 72 hours with DMSO Vehicle as control, and Unesbulin or PTC-028. Protein lysates were immunoblotted with an anti-BMI-1 or an anti-Tubulin antibody. Loading was assessed with an anti-β-actin antibody. Expected size is shown in kDa. The slower migrating hyperphosphorylated BMI-1 band is indicated by the arrowhead. B, Cell cycle analysis of the H1975 cell lines after treatment for 24 hours with DMSO (black), Unesbulin (light blue), or PTC-028 (dark blue). The bar charts represent the distribution of cells in G0, G1, and G2–M phases. P values are indicated. Error bars represent SD. Percentages of cells in each cell cycle phase are indicated. C, H1975 xenografts tumor volumes at treatment termination (Vehicle n = 15, black; Unesbulin n = 17, light blue; PTC208 n = 8, dark blue) normalized to the tumor volume measured at the beginning of treatment. The difference in tumor size at day 21 was statistically significant (P values are indicated). D, The graph shows percentage of change in transgenic mice tumor volume measured by MRI at the indicated timepoints, between Unesbulin (n = 8, light blue) and Vehicle-treated (n = 6, black) groups. Error bars represent SD. P value is indicated. E, Confocal microscopy fluorescence nuclear imaging of DNA and H2AK119ub in tumor tissues collected at the end of treatment. Top panels show a representative image of DMSO-treated tumor; bottom panels show a tumor treated with Unesbulin. Left panels show DNA staining by Hoechst 33342 (blue acquisition channel). Right panels show H2AK119ub staining by immunofluorescence (scale bar, 10 µm).
- 10 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 1 from Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment
BMI-1 inhibition affects cell cycle progression and tumor growth. A, Western blot analyses of the human H1975 cell line treated for 24, 48, and 72 hours with DMSO Vehicle as control, and Unesbulin or PTC-028. Protein lysates were immunoblotted with an anti-BMI-1 or an anti-Tubulin antibody. Loading was assessed with an anti-β-actin antibody. Expected size is shown in kDa. The slower migrating hyperphosphorylated BMI-1 band is indicated by the arrowhead. B, Cell cycle analysis of the H1975 cell lines after treatment for 24 hours with DMSO (black), Unesbulin (light blue), or PTC-028 (dark blue). The bar charts represent the distribution of cells in G0, G1, and G2–M phases. P values are indicated. Error bars represent SD. Percentages of cells in each cell cycle phase are indicated. C, H1975 xenografts tumor volumes at treatment termination (Vehicle n = 15, black; Unesbulin n = 17, light blue; PTC208 n = 8, dark blue) normalized to the tumor volume measured at the beginning of treatment. The difference in tumor size at day 21 was statistically significant (P values are indicated). D, The graph shows percentage of change in transgenic mice tumor volume measured by MRI at the indicated timepoints, between Unesbulin (n = 8, light blue) and Vehicle-treated (n = 6, black) groups. Error bars represent SD. P value is indicated. E, Confocal microscopy fluorescence nuclear imaging of DNA and H2AK119ub in tumor tissues collected at the end of treatment. Top panels show a representative image of DMSO-treated tumor; bottom panels show a tumor treated with Unesbulin. Left panels show DNA staining by Hoechst 33342 (blue acquisition channel). Right panels show H2AK119ub staining by immunofluorescence (scale bar, 10 µm).
- Open Access
- 10 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 10 from Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment
Supplementary Table 10. Size of each identified transcriptional cluster as percentage of all profiled cells.
- 10 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 10 from Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment
Supplementary Table 10. Size of each identified transcriptional cluster as percentage of all profiled cells.
- Open Access
- 10 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment
Supplementary Table 6. Size of each identified transcriptional cluster as percentage of all profiled cells.
- 10 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment
Supplementary Table 6. Size of each identified transcriptional cluster as percentage of all profiled cells.
- Open Access
- 10 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 14 from Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment
Supplementary Table 14. Size of each identified transcriptional cluster as percentage of all profiled fibroblasts.
- 10 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 14 from Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment
Supplementary Table 14. Size of each identified transcriptional cluster as percentage of all profiled fibroblasts.
- Open Access
- 10 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 12 from Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment
Supplementary Table 12. Size of each identified transcriptional cluster as percentage of all profiled endothelial cells.
- 10 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 12 from Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment
Supplementary Table 12. Size of each identified transcriptional cluster as percentage of all profiled endothelial cells.
- Open Access
- 10 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment
Supplementary Table 1. Size of each identified transcriptional cluster as percentage of all profiled cells.
- 10 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment
Supplementary Table 1. Size of each identified transcriptional cluster as percentage of all profiled cells.
- Open Access
- 10 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 8 from Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment
Supplementary Table 8. Size of each identified cell type as a percentage of all profiled cells.
- 10 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 8 from Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment
Supplementary Table 8. Size of each identified cell type as a percentage of all profiled cells.
- Open Access
- 10 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment
Supplementary Table 4. Size of each identified cell type as a percentage of all profiled cells.
- 10 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment
Supplementary Table 4. Size of each identified cell type as a percentage of all profiled cells.